Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 48 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06020755 | Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7(TA7) | recruiting | Phase 2 | 17 | Peking Union Medical College HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06751277 | QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer | not yet recruiting | Phase 2 | 26 | xiang yangOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | active not recruiting | Phase 2 | 118 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06684327 | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06730672 | An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04507841 | Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 67 | Tongji HospitalOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06735326 | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | recruiting | Phase 2 | 105 | Qilu Hospital of Shandong UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases(STORM) | active not recruiting | Phase 2 | 196 | University Hospital, GhentOTHER | 6 | Dec 9, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer(ABATE) | active not recruiting | Phase 2 | 46 | Deepak KilariOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04562311 | Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04861584 | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | recruiting | Phase 2 | 41 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT06582628 | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)(TEAM PC) | recruiting | Phase 2 | 78 | Fundacion OncosurNETWORK | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05652283 | Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 37 | Bai-Rong XiaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | recruiting | Phase 2 | 74 | Anhui Provincial Cancer HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05393791 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC(ANZadapt) | recruiting | Phase 2 | 168 | Leiden University Medical CenterOTHER | 2 | Nov 26, 2024 | clinicaltrials |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | not yet recruiting | Phase 2 | 79 | Fudan UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04879563 | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project(ASCAPE) | active not recruiting | Phase 2 | 500 | Region Örebro CountyOTHER | 4 | Nov 19, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06639347 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 90 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial(HPV-VIM) | recruiting | Phase 2 | 85 | Baylor College of MedicineOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy(LuTectomy) | active not recruiting | Phase 1 / Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681636 | Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure(HPV9vxFSW) | not yet recruiting | Phase 2 | 300 | National Institute of Hygiene and Epidemiology, VietnamOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT06289062 | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | recruiting | Phase 2 / Phase 3 | 440 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06663007 | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure | recruiting | Phase 1 / Phase 2 | 72 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06617481 | PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence | recruiting | Phase 2 | 30 | AdventHealthOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS) | not yet recruiting | Phase 2 | 40 | British Columbia Cancer AgencyOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06655259 | Combination of TURP and Standard Systemic Therapy for MPCa(CTUSMEP01) | recruiting | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05558007 | Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients | recruiting | Phase 2 | 72 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2025source: clinicaltrials